Health Robotics today announced that its joint venture Health Robotics South East Asia Ltd. scored two strategic wins by reaching agreements on two separate government-sponsored projects to deliver CytoCare-made accurate and sterile oncology patient doses in Kuala Lumpur and Bangkok, respectively. Health Robotics' CytoCare is the first and only robot in the world proven to automatically compound and dispense oncology intravenous therapy treatments to patients.
Health Robotics South East Asia announced the opening of two outsourcing centers within close distance to Kuala Lumpur General Hospital in 4Q2010 and the National Cancer Institute Thailand in 1Q 2011, respectively. These two key projects consolidate the leadership position of Health Robotics SEA within Private Finance Initiatives (PFIs) in the region [PFIs are initiatives that, in addition to products and services, provide financial support under public-private partnerships]. The contracted plan for the outsourcing centers already includes the purchase of CytoCare and i.v.STATION robotic devices, and a state-of-the-art logistics system already in place for other medical supplies. These assets will be complemented by Health Robotics SEA's future selection of strategic partners for compounding services, IV consumables, and both generic and proprietary oncology medications to be used in the 2 centers, all currently in the process of vendor selection.
"I'm very pleased that our South East Asia joint venture's chemotherapy outsourcing and PFI strategies are beginning to produce outstanding results. I look forward to their future expansion to all government-owned hospitals in Malaysia and Thailand, as well as quick geographical expansion into other countries in the region, such as Singapore, India and Vietnam. We are firm believers that the 'pay-per-dose' outsourcing business model is an excellent fit for our best-in-class technology and workflow processes in the region, offering a win-win scenario to capital-starved public hospitals. I have personally witnessed in Turkey the excellent results of a similar 'pay-per-dose' outsourcing model in combination with a government-sponsored partnership, resulting in orders for 24 CytoCare robots within the past 2 years from our Turkish strategic partner Rivosem. We plan similar 'pay-per-dose' outsourcing business models wherever applicable, including selected countries in Western Europe," stated Werner Rainer, Health Robotics' CEO.